Citadel Advisors
UNCY icon

Citadel Advisors’s Unicycive Therapeutics UNCY Stock Holding History

Citadel Advisors’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$167K Buy
25,400
+14,500
+133% +$95K ﹤0.01% 11590
2025
Q4 		$62.9K Buy
+10,900
New +$58.2K ﹤0.01% 11924

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's UNCY Position: Q1 2026 in Review

Citadel Advisors reduced its Unicycive Therapeutics (UNCY) stake by 8.3% in Q1 2026, selling an estimated $141K and leaving 236,841 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #6635.

Citadel Advisors first reported a position in UNCY in Q1 2022 and has held it in 7 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Citadel Advisors held 236,841 shares of Unicycive Therapeutics worth $1.56M as of Q1 2026.
  • Citadel Advisors sold 21,460 Unicycive Therapeutics shares in Q1 2026, an estimated $141K.
  • Unicycive Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6635 holding.
  • Citadel Advisors first reported a position in Unicycive Therapeutics in Q1 2022 and has held it in 7 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.